Aytu Bioscience (AYTU) Earns News Sentiment Rating of 0.31
News articles about Aytu Bioscience (NASDAQ:AYTU) have trended positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aytu Bioscience earned a news impact score of 0.31 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 47.9170828401986 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Aytu Bioscience (NASDAQ:AYTU) traded down $0.03 during trading hours on Friday, hitting $2.55. 22,530 shares of the stock traded hands, compared to its average volume of 43,051. Aytu Bioscience has a twelve month low of $2.35 and a twelve month high of $26.80.
Aytu Bioscience (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($1.76) EPS for the quarter, beating the consensus estimate of ($7.60) by $5.84. Aytu Bioscience had a negative net margin of 481.06% and a negative return on equity of 229.64%. The business had revenue of $1.08 million during the quarter.
COPYRIGHT VIOLATION WARNING: “Aytu Bioscience (AYTU) Earns News Sentiment Rating of 0.31” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/aytu-bioscience-aytu-earns-news-sentiment-rating-of-0-31/1756295.html.
About Aytu Bioscience
Aytu BioScience, Inc is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer.
Receive News & Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.